{"product_id":"sxtp-marketing-mix","title":"(SXTP) 60 Degrees Pharmaceuticals, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis 60 Degrees Pharmaceuticals, Inc. 4P's Marketing Mix Analysis shows the company’s Product, Price, Place and Promotion strategy and explains what the offering is and how it’s used; the page already includes a real preview\/sample of the analysis so you can review style and content before buying — purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1 approved product: Arakoda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda is 60 Degrees Pharmaceuticals’ only approved commercial product and the company’s marketed asset. It is a tafenoquine-based malaria prophylaxis for adults, giving the firm a revenue platform while it advances its pipeline. As the only approved product, Arakoda anchors the Product mix with a clear, FDA-cleared treatment offering in a niche malaria-prevention market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase IIb tafenoquine for COVID-19\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. is studying tafenoquine in Phase IIb for COVID-19 using the Arakoda regimen, extending one active ingredient beyond malaria prevention. Arakoda is already the Company Name’s FDA-approved malaria prophylaxis product, so this trial tests whether the same asset can support a broader infectious-disease platform. If successful, it could improve asset reuse and raise the commercial value of tafenoquine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase IIA tafenoquine for 3 indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase IIA tafenoquine spans babesiosis, fungal pneumonias, and candidiasis, keeping 60 Degrees Pharmaceuticals, Inc. squarely in infectious disease. The three programs widen the drug’s addressable market beyond malaria and support pipeline depth if results hold. For a small-cap biotech, that kind of multi-indication reuse can lower development risk and raise future revenue upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCelgosivir for 3 viral diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCelgosivir gives 60 Degrees Pharmaceuticals, Inc. a second investigational asset beyond tafenoquine, and it is being developed for 3 viral disease areas: Zika, respiratory viruses, and dengue fever. That broader pipeline can reduce single-asset risk and widen future use cases. One asset, 3 shots at value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 target viral disease areas\u003c\/li\u003e\n\u003cli\u003eSecond investigational asset\u003c\/li\u003e\n\u003cli\u003eBroadens portfolio beyond tafenoquine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTufts Medical Center license for babesiosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. holds a patent license agreement with Tufts Medical Center for tafenoquine in babesiosis, a niche tick-borne disease market. The deal supports product development rights for both treatment and prevention, which can widen the Company Name's pipeline value without needing a full new-drug discovery program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTufts Medical Center backs tafenoquine rights\u003c\/li\u003e\n\u003cli\u003eTargets babesiosis treatment and prevention\u003c\/li\u003e\n\u003cli\u003eStrengthens niche infectious-disease positioning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne Approved Drug, Multiple Pipeline Shots for 60 Degrees Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArakoda is 60 Degrees Pharmaceuticals, Inc.'s only approved product and the core of its Product mix, giving the Company Name one FDA-cleared malaria prophylaxis asset. Beyond malaria, tafenoquine is also being tested in Phase IIb COVID-19 and Phase IIA babesiosis, fungal pneumonia, and candidiasis, so one molecule supports multiple shots at value. Celgosivir adds a second investigational asset across Zika, respiratory viruses, and dengue fever.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArakoda\u003c\/td\u003e\n\u003ctd\u003eApproved\u003c\/td\u003e\n\u003ctd\u003eMalaria prophylaxis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTafenoquine pipeline\u003c\/td\u003e\n\u003ctd\u003ePhase IIb \/ IIA\u003c\/td\u003e\n\u003ctd\u003eCOVID-19, babesiosis, fungal pneumonia, candidiasis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCelgosivir\u003c\/td\u003e\n\u003ctd\u003eInvestigational\u003c\/td\u003e\n\u003ctd\u003eZika, respiratory viruses, dengue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P’s analysis of 60 Degrees Pharmaceuticals, Inc. showing how Product, Price, Place, and Promotion shape its market strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses 60 Degrees Pharmaceuticals’ 4Ps into a quick, clear view that simplifies decision-making and marketing alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, government data, and benchmarks to quickly verify 60 Degrees Pharmaceuticals’ market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWashington, D.C. headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., placing key decisions in the U.S. capital. That location gives the Company direct access to federal regulators, policy makers, and investors. Washington, D.C. has about 700,000 residents and a dense institutional network, which supports visibility and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. infectious-disease focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. keeps its place strategy centered on the U.S. infectious-disease market, not a wide consumer retail network. The company’s U.S.-first footprint fits its FDA-regulated products and small scale, with 2025 filings showing a market value near $20 million and a very limited commercial base. That makes the United States the core geography in its marketing mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription-access model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda is a prescription-only antimalarial, so access runs through U.S. healthcare providers and pharmacies, not OTC shelves. The FDA approved Arakoda in 2018, and its weekly dosing plus prescription status keep the product tied to clinical prescribing and pharmacy dispensing. That makes the place strategy a regulated distribution model, not direct retail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-development sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. depends on clinical-development sites for its Phase IIb and Phase IIA trials, where investigational products are dosed and measured against protocol endpoints. These sites are a core part of the Company Name's development path because they determine enrollment speed, data quality, and trial cost. The company has not publicly broken out a site count in recent filings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase IIb and Phase IIA sites drive execution.\u003c\/li\u003e\n\u003cli\u003eThey administer and assess investigational products.\u003c\/li\u003e\n\u003cli\u003eNo public site-count disclosure was found.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic partnership channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Tufts Medical Center license gives 60 Degrees Pharmaceuticals, Inc. one U.S. academic medical institution channel for research and disease-specific expertise. That place-based link can speed access to clinical know-how, support development work beyond internal teams, and widen the company’s reach without building a full in-house academic network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 academic medical partner\u003c\/li\u003e\n\u003cli\u003eU.S.-based collaboration channel\u003c\/li\u003e\n\u003cli\u003eExpands research access\u003c\/li\u003e\n\u003cli\u003eSupports disease-specific expertise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e60 Degrees’ U.S.-First Strategy Keeps Growth Narrow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. uses a U.S.-first place strategy: Washington, D.C. for corporate access, U.S. pharmacies and prescribers for Arakoda, and trial sites for Phase IIb and Phase IIA work. With a 2025 market value near $20 million and no public site count, its reach stays narrow and regulated.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eWashington, D.C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct access\u003c\/td\u003e\n\u003ctd\u003ePrescription-only U.S. pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003ePhase IIb, Phase IIA sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 market value\u003c\/td\u003e\n\u003ctd\u003eNear $20 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e60 Degrees Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual 4P's Marketing Mix analysis for 60 Degrees Pharmaceuticals, Inc. you’ll receive instantly after purchase—fully complete, editable, and ready to use with product, price, place, and promotion insights tailored to the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA-approved product message\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda, approved by the FDA in December 2018, is 60 Degrees Pharmaceuticals, Inc.'s main promotional proof point. One regulated product in market makes the brand easier to trust, because it shows the company can meet FDA standards and support commercialization. That credibility can help lower resistance when the firm promotes its pipeline and future label expansion plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-trial milestone updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical-trial milestone updates are a core promotion tool for 60 Degrees Pharmaceuticals, Inc., with Phase IIb and Phase IIA progress signaling real pipeline traction to investors, partners, and clinicians. The company uses these readouts to keep the story moving while commercial sales stay limited, and mid-stage data often matter more than near-term revenue. Each milestone can support value, since one positive trial update can shift attention faster than a small sales base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfectious-disease specialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. keeps its promotion tight around infectious diseases, so the brand reads as a specialist, not a broad pharma player. Its lead product, ARAKODA, is a tafenoquine malaria drug approved by the U.S. FDA, which gives the message a clear high-need focus. That niche positioning helps the company stand out in a small but clinically urgent market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTufts collaboration announcement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc.'s patent license agreement with Tufts Medical Center is a strong promotion point because it shows outside scientific backing and adds credibility to the pipeline. For investors and stakeholders, a named research partner can reduce perceived development risk and support confidence in the Company’s R\u0026amp;D story.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTufts deal signals validation\u003c\/li\u003e\n\u003cli\u003eBoosts scientific credibility\u003c\/li\u003e\n\u003cli\u003eSupports investor confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic-company disclosures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. uses SEC filings, press releases, and investor materials to share product, pipeline, and corporate updates. For a U.S. listed company, these channels matter most when a promotion is tied to clinical milestones, since the filing trail and public releases give investors a clear record of progress and risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSEC filings support formal disclosure.\u003c\/li\u003e\n\u003cli\u003ePress releases speed milestone updates.\u003c\/li\u003e\n\u003cli\u003eInvestor decks explain pipeline plans.\u003c\/li\u003e\n\u003cli\u003eClinical data can drive promotion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArakoda Approval and Clinical Updates Drive 60 Degrees Promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePromotion at 60 Degrees Pharmaceuticals, Inc. is built on Arakoda’s FDA approval, malaria focus, and clinical updates that keep the pipeline visible. SEC filings, press releases, and investor materials are the main channels, while the Tufts Medical Center license adds scientific credibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003ePromotion value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArakoda FDA-approved\u003c\/td\u003e\n\u003ctd\u003eTrust anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase IIb\/IIA updates\u003c\/td\u003e\n\u003ctd\u003ePipeline visibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTufts license\u003c\/td\u003e\n\u003ctd\u003eScientific validation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArakoda price not disclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda price is not disclosed in the supplied Company Name data, so exact pricing cannot be verified here.\u003c\/p\u003e\n\u003cp\u003eThat means Company Name’s commercial price point for Arakoda is not stated in this material, and no public list price is provided.\u003c\/p\u003e\n\u003cp\u003eWithout a disclosed 2025\/2026 price, the pricing element of the 4P mix stays unconfirmed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1 marketed product, 4 pipeline programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. has 1 marketed product and 4 pipeline programs, so price today is tied to the approved product only. The company’s investigational candidates have no commercial pricing yet, since they are still in development. For pricing, the focus is on access, reimbursement, and net realized sales for the marketed product, not the pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription-market pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArakoda is an FDA-approved prescription drug, so its price is set inside the U.S. reimbursement system, where payers, pharmacies, and patient cost-sharing shape access. In 2025, Medicare Part D capped annual out-of-pocket drug costs at $2,000, which can matter for insured patients, but 60 Degrees Pharmaceuticals, Inc. did not disclose specific reimbursement terms. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo public discount terms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. does not disclose public discount terms, so rebates, financing, and credit options are not visible in the company summary. That leaves the price structure unclear for buyers and investors, with no stated price breaks or trade incentives. In its latest public materials, the company still provides no quantified discount policy.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo disclosed rebates or markdowns\u003c\/li\u003e\n\u003cli\u003eNo financing or credit terms published\u003c\/li\u003e\n\u003cli\u003ePricing remains unspecified\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty anti-infective economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. sells into specialty anti-infective markets, where demand is narrow and tied to clinical need, not mass retail volume. That makes price less about unit traffic and more about access, payer support, and proof of value, especially for products like ARAKODA used in malaria prevention.\u003c\/p\u003e\n\u003cp\u003eIn niche infectious-disease care, a higher list price can work only if it supports reimbursement and fits hospital, travel-medicine, or government buying channels. The company’s economics are shaped by small patient pools, high development cost, and the need to defend value with outcomes, safety, and convenience data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall patient base\u003c\/li\u003e\n\u003cli\u003eAccess drives pricing power\u003c\/li\u003e\n\u003cli\u003eValue proof matters most\u003c\/li\u003e\n\u003cli\u003ePayer and channel mix set realization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARAKODA Price Unlisted, But Medicare Cap Shapes 2025 Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e60 Degrees Pharmaceuticals, Inc. does not disclose a public 2025\/2026 list price for ARAKODA, so the price point cannot be verified from supplied data. Pricing is therefore driven by payer access, pharmacy channels, and patient cost-sharing, not a stated sticker price. Medicare Part D’s $2,000 annual out-of-pocket cap in 2025 can affect insured buyers. No rebates, discounts, or credit terms were disclosed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice factor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eARAKODA list price\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D OOP cap\u003c\/td\u003e\n\u003ctd\u003e$2,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscount terms\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235118981385,"sku":"sxtp-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sxtp-marketing-mix.webp?v=1785733018","url":"https:\/\/dcfanalyst.com\/products\/sxtp-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}